BENZYL BENZOATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BENZYL BENZOATE (BENZYL BENZOATE).
Benzyl benzoate is a scabicidal agent that disrupts the nervous system of mites by interacting with sodium channels, leading to paralysis and death.
| Metabolism | Metabolized primarily by hydrolysis to benzoic acid and benzyl alcohol, which are further conjugated with glycine to form hippuric acid and excreted renally. |
| Excretion | Renal (excreted as hippuric acid and benzoic acid conjugates, ~75-90%); biliary/fecal (minor, ~10-25%) |
| Half-life | 6-9 hours in plasma; clinical context: supports twice-daily application for scabies/lice |
| Protein binding | Approximately 90-95% bound to albumin (primarily) and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5-1.0 L/kg; indicates extensive distribution into tissues, including skin and adipose |
| Bioavailability | Topical: variable but estimated at 5-15% systemic absorption through intact skin; oral: not applicable as not used systemically |
| Onset of Action | Topical: scabicidal effect begins within 24-48 hours; oral: not applicable |
| Duration of Action | After single topical application, antiparasitic effect persists 24-48 hours; requires repeat application at 24 hours; clinical note: residual activity may last up to 72 hours |
Apply 25% lotion or 10% cream to entire body (excluding face, scalp, and mucous membranes) once daily at bedtime for 2-5 days, or as a single 24-hour application; repeat after 7 days if needed. For scabies: 25% lotion applied from neck to toes, wash off after 24 hours; second application may be given at 1-week interval.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is minimal (<2%). For oral use (rare), no specific GFR-based guidelines; avoid in severe renal impairment due to potential benzoate accumulation. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption is minimal. For oral use, avoid in severe hepatic impairment (Child-Pugh C) due to risk of benzoate toxicity and impaired metabolism. |
| Pediatric use | Infants and children: For scabies, apply 10% cream or 25% lotion (diluted to 10% for infants <1 year) to whole body except face; wash off after 6-12 hours. For lice, apply 25% lotion to affected areas, wash off after 12-24 hours. Contraindicated in neonates and infants <2 months due to benzyl alcohol toxicity risk. |
| Geriatric use | No specific dose adjustment; use with caution in elderly due to thinner skin, increased systemic absorption, and higher risk of skin irritation. Monitor for cutaneous adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BENZYL BENZOATE (BENZYL BENZOATE).
| Breastfeeding | There is no data on benzyl benzoate excretion into breast milk. The M/P ratio is unknown. Due to minimal systemic absorption from topical application, risk to a nursing infant is likely low. However, avoid application to the breast area to prevent infant ingestion. |
| Teratogenic Risk | Benzyl benzoate is not known to be teratogenic based on limited animal studies and human case reports. No specific fetal risks have been identified in any trimester, but due to lack of robust human data, use during pregnancy should be cautious, especially in the first trimester. Applied topically, systemic absorption is minimal, reducing theoretical risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to benzyl benzoate or any component of the formulation.
| Precautions | Avoid contact with eyes, mucous membranes, and broken skin. Use with caution in children and during pregnancy. Discontinue if severe irritation or allergic reaction occurs. |
| Food/Dietary | No known food interactions. Avoid excessive consumption of alcohol due to potential for increased irritation or systemic absorption; however, no formal interaction documented. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required beyond standard pregnancy care. If used in pregnancy, monitor for maternal skin irritation or allergic reactions. No fetal monitoring indicated. |
| Fertility Effects | There is no evidence that benzyl benzoate affects human fertility. Animal studies have not reported adverse effects on fertility. Topical use minimizes systemic exposure. |
| Apply topically only; avoid contact with eyes, mucous membranes, and broken skin. Use a 25% concentration for scabies; for pediculosis, use a 25% dilution. May cause stinging or irritation on excoriated skin. Not recommended for children under 2 years due to risk of neurological toxicity. Consider second-line therapy after permethrin failure. Can be used in pregnancy (category C) if benefits outweigh risks. |
| Patient Advice | Apply a thin layer to the entire body from neck to toes, avoiding the face and scalp. · Leave on for 24 hours, then wash off thoroughly with soap and water. · Treat all close contacts and household members simultaneously. · Wash all bedding, clothing, and towels in hot water and dry on high heat. · Do not apply to broken skin, eyes, or mucous membranes. · Do not use more than once a day; avoid prolonged use. · If accidental contact with eyes occurs, rinse with plenty of water and seek medical attention. · Store at room temperature away from heat and open flame. |